Moderated by Dr. Chin-Sheng Hung, Director of Medical Affairs at Taipei Medical University Hospital, and presented by Dr. Wei-Wen Chang, Director of Surgery at Wan Fang Hospital, this lecture will explore how recurrence risk in HR+/HER2− early breast cancer extends beyond high-risk populations, highlighting the need for individualized treatment strategies that balance efficacy with long-term tolerability. The session will review the biological and clinical rationale for treatment escalation, including adjuvant CDK4/6 inhibitors, discuss the impact of treatment-related adverse events on treatment adherence and outcomes, and explore emerging challenges and therapeutic considerations in the post-progression setting.
台灣諾華股份有限公司
台灣諾華承續全球的目標和願景，以研發創新藥品來治療疾病、減輕疾病帶來的痛苦，並提昇病患的生活品質。期望符合甚且超越外界期許，致力創造永續成長，保持業界前茅，維持長期經營成效。希望贏得優異工作環境的美譽、營造鼓勵創新與效率的環境，並能適時回饋社會。